Robert A. Hauser

30.7k total citations · 4 hit papers
358 papers, 18.9k citations indexed

About

Robert A. Hauser is a scholar working on Neurology, Psychiatry and Mental health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Robert A. Hauser has authored 358 papers receiving a total of 18.9k indexed citations (citations by other indexed papers that have themselves been cited), including 287 papers in Neurology, 66 papers in Psychiatry and Mental health and 58 papers in Cellular and Molecular Neuroscience. Recurrent topics in Robert A. Hauser's work include Parkinson's Disease Mechanisms and Treatments (248 papers), Neurological disorders and treatments (200 papers) and Botulinum Toxin and Related Neurological Disorders (56 papers). Robert A. Hauser is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (248 papers), Neurological disorders and treatments (200 papers) and Botulinum Toxin and Related Neurological Disorders (56 papers). Robert A. Hauser collaborates with scholars based in United States, Canada and France. Robert A. Hauser's co-authors include C. Warren Olanow, Thomas B. Freeman, Jeffrey H. Kordower, Olivier Rascol, Yaping Chu, Theresa A. Zesiewicz, Werner Poewe, Anthony E. Lang, Joseph Jankovic and Rajesh Pahwa and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Robert A. Hauser

345 papers receiving 18.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

2008 1.2k citations Jeffrey H. Kordower, Yaping Chu et al. profile →
Neuropathological Evidence of Graft Survival and Striatal Reinnervation after the Transplantation of Fetal Mesencephalic Tissue in a Patient with Parkinson's Disease

1995 671 citations Jeffrey H. Kordower, Thomas B. Freeman et al. New England Journal of Medicine profile →
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study

2003 604 citations Robert A. Hauser et al. profile →
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

2009 587 citations C. Warren Olanow, Robert A. Hauser et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert A. Hauser United States	74	13.7k	6.8k	3.0k	2.1k	1.8k	358	18.9k
Wolfgang H. Oertel Germany	71	15.9k 1.2×	6.0k 0.9×	3.5k 1.2×	3.6k 1.7×	2.2k 1.2×	292	23.4k
Olivier Rascol France	86	20.8k 1.5×	7.7k 1.1×	2.5k 0.8×	4.7k 2.2×	2.7k 1.5×	434	27.5k
J. Eric Ahlskog United States	80	13.3k 1.0×	5.2k 0.8×	1.9k 0.6×	2.4k 1.1×	2.1k 1.2×	279	19.9k
Stephen J. Kish Canada	73	6.3k 0.5×	9.5k 1.4×	5.6k 1.9×	1.7k 0.8×	1.5k 0.9×	284	17.9k
Nicola Biagio Mercuri Italy	69	4.9k 0.4×	10.5k 1.6×	6.3k 2.1×	4.2k 2.0×	1.8k 1.0×	566	19.5k
Diego Centonze Italy	81	4.8k 0.4×	10.2k 1.5×	6.4k 2.1×	3.2k 1.5×	1.1k 0.6×	487	23.3k
Michael A. Schwarzschild United States	72	7.6k 0.6×	5.1k 0.8×	4.5k 1.5×	1.2k 0.6×	865 0.5×	235	17.3k
Kenneth Marek United States	52	9.9k 0.7×	3.5k 0.5×	1.8k 0.6×	1.8k 0.9×	1.2k 0.7×	189	13.5k
Eldad Melamed Israel	65	6.0k 0.4×	4.5k 0.7×	3.7k 1.2×	819 0.4×	949 0.5×	228	13.6k
A. Jon Stoessl Canada	65	9.8k 0.7×	6.5k 1.0×	3.4k 1.1×	2.7k 1.3×	1.3k 0.7×	317	16.5k

Countries citing papers authored by Robert A. Hauser

Since Specialization

Citations

This map shows the geographic impact of Robert A. Hauser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Hauser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Hauser more than expected).

Fields of papers citing papers by Robert A. Hauser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Hauser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Hauser. The network helps show where Robert A. Hauser may publish in the future.

Co-authorship network of co-authors of Robert A. Hauser

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Hauser. A scholar is included among the top collaborators of Robert A. Hauser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Hauser. Robert A. Hauser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hauser, Robert A., et al.. (2025). VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review. CNS Spectrums. 30(1). e90–e90.

Hauser, Robert A., Hubert H. Fernandez, Joohi Jimenez‐Shahed, et al.. (2024). Duration of “Good On” time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT®). Parkinsonism & Related Disorders. 131. 107239–107239. 1 indexed citations

Martino, Davide, Vikram Karnik, Roongroj Bhidayasiri, et al.. (2023). Scales for Antipsychotic‐Associated Movement Disorders: Systematic Review, Critique, and Recommendations. Movement Disorders. 38(6). 1008–1026. 3 indexed citations

Hauser, Robert A., Alberto J. Espay, Aaron Ellenbogen, et al.. (2023). IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease. JAMA Neurology. 80(10). 1062–1062. 20 indexed citations

Espay, Alberto J., Robert A. Hauser, Rohit Dhall, et al.. (2023). Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE‐PD Open‐Label Extension Study. Movement Disorders. 39(2). 428–432. 4 indexed citations

Jankovic, Joseph, Cynthia Comella, Robert A. Hauser, et al.. (2021). A Phase 3 Trial Evaluating the Efficacy, Duration of Effect, and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Cervical Dystonia (1478). Neurology. 96(15_supplement). 2 indexed citations

Hauser, Robert A., Aaron Ellenbogen, Sarita Khanna, Suneel Gupta, & Nishit B. Modi. (2018). Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease. Neuropsychiatric Disease and Treatment. Volume 14. 839–845. 13 indexed citations

François, C., Gerald J. Rowse, L. Arthur Hewitt, Pamela Vo, & Robert A. Hauser. (2016). Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension. BMC Neurology. 16(1). 143–143. 3 indexed citations

Tetrud, James W., Paul A. Nausieda, Grace Liang, et al.. (2016). Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. Journal of the Neurological Sciences. 373. 116–123. 4 indexed citations

10.

Pahwa, Rajesh, Caroline M. Tanner, Robert A. Hauser, et al.. (2015). Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study). Movement Disorders. 30(6). 788–795. 113 indexed citations

11.

Simon, David K., Cai Wu, Barbara C. Tilley, et al.. (2015). Caffeine and Progression of Parkinson Disease. Clinical Neuropharmacology. 38(5). 163–169. 20 indexed citations

12.

Han, Yanfu, et al.. (2014). A Mixed Treatment Comparison (Mtc) To Compare The Efficacy Of Botulinum Toxin Type A Treatments For Cervical Dystonia. Value in Health. 17(3). A57–A57. 2 indexed citations

13.

Cicchetti, Francesca, Samuel Saporta, Robert A. Hauser, et al.. (2009). Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proceedings of the National Academy of Sciences. 106(30). 12483–12488. 142 indexed citations

14.

Samanta, Johan & Robert A. Hauser. (2007). Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opinion on Pharmacotherapy. 8(5). 657–664. 35 indexed citations

15.

Zesiewicz, Theresa A., et al.. (2006). A double‐blind placebo‐controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Movement Disorders. 22(2). 279–282. 58 indexed citations

16.

Hauser, Robert A., F. Deckers, & Philippe Lehert. (2004). Parkinson's disease home diary: Further validation and implications for clinical trials. Movement Disorders. 19(12). 1409–1413. 144 indexed citations

17.

Weiner, William J., Stewart A. Factor, Joseph Jankovic, et al.. (2001). The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism & Related Disorders. 7(2). 115–120. 29 indexed citations

18.

Freeman, Thomas B., Dorothy E. Vawter, P E Leaverton, et al.. (1999). Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease. New England Journal of Medicine. 341(13). 988–992. 157 indexed citations

19.

Freeman, Thomas B., Dorothy E. Vawter, Christopher G. Goetz, et al.. (1997). Toward the use of surgical placebo-controlled trials. Transplantation Proceedings. 29(4). 1925–1925. 3 indexed citations

20.

Switzerland, et al.. (1983). StGB, Schweizerisches Strafgesetzbuch : das Bundesgesetz vom 21. Dezember 1937, in Kraft seit 1. Januar 1942, mit allen seitherigen Änderungen und Ergänzungen : Gesetzestext mit Anmerkungen, Anhang von weiteren Erlassen und Sachregister. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact